In the past week, SPRB stock has gone down by -0.55%, with a monthly decline of -1.66% and a quarterly plunge of -14.11%. The volatility ratio for the week is 5.02%, and the volatility levels for the last 30 days are 4.69% for Spruce Biosciences Inc The simple moving average for the past 20 days is -1.84% for SPRB’s stock, with a -71.29% simple moving average for the past 200 days.
Is It Worth Investing in Spruce Biosciences Inc (NASDAQ: SPRB) Right Now?
The 36-month beta value for SPRB is also noteworthy at 2.40. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SPRB is 28.51M, and at present, short sellers hold a 0.88% of that float. The average trading volume of SPRB on September 19, 2024 was 426.61K shares.
SPRB) stock’s latest price update
Spruce Biosciences Inc (NASDAQ: SPRB) has seen a rise in its stock price by 1.70 in relation to its previous close of 0.45. However, the company has experienced a -0.55% decline in its stock price over the last five trading sessions. accesswire.com reported 2024-09-19 that LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. (“Spruce” or “the Company”) (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Analysts’ Opinion of SPRB
Many brokerage firms have already submitted their reports for SPRB stocks, with RBC Capital Mkts repeating the rating for SPRB by listing it as a “Sector Perform.” The predicted price for SPRB in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on March 14, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see SPRB reach a price target of $2, previously predicting the price at $9. The rating they have provided for SPRB stocks is “Market Perform” according to the report published on March 14th, 2024.
SPRB Trading at -6.62% from the 50-Day Moving Average
After a stumble in the market that brought SPRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.35% of loss for the given period.
Volatility was left at 4.69%, however, over the last 30 days, the volatility rate increased by 5.02%, as shares sank -4.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.84% lower at present.
During the last 5 trading sessions, SPRB fell by -0.55%, which changed the moving average for the period of 200-days by -69.45% in comparison to the 20-day moving average, which settled at $0.4626. In addition, Spruce Biosciences Inc saw -84.46% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRB starting from Novo Holdings A/S, who sale 465,021 shares at the price of $0.75 back on Mar 21 ’24. After this action, Novo Holdings A/S now owns 2,550,000 shares of Spruce Biosciences Inc, valued at $350,951 using the latest closing price.
Novo Holdings A/S, the 10% Owner of Spruce Biosciences Inc, sale 842,020 shares at $0.77 during a trade that took place back on Mar 18 ’24, which means that Novo Holdings A/S is holding 3,968,000 shares at $647,008 based on the most recent closing price.
Stock Fundamentals for SPRB
Current profitability levels for the company are sitting at:
- -4.96 for the present operating margin
- 0.99 for the gross margin
The net margin for Spruce Biosciences Inc stands at -4.5. The total capital return value is set at -0.78. Equity return is now at value -55.37, with -42.79 for asset returns.
Based on Spruce Biosciences Inc (SPRB), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -17.62. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -284.38.
Currently, EBITDA for the company is -51.92 million with net debt to EBITDA at 1.39. When we switch over and look at the enterprise to sales, we see a ratio of -4.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.17.
Conclusion
In summary, Spruce Biosciences Inc (SPRB) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
